Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.

Barone A, Chi DC, Theoret MR, Chen H, He K, Kufrin D, Helms WS, Subramaniam S, Zhao H, Patel A, Goldberg KB, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Dec 15;23(24):7448-7453. doi: 10.1158/1078-0432.CCR-17-0898. Epub 2017 Aug 3.


FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.

Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, Helms WS, Jin R, Li H, Yu J, Zhao H, Zhao L, Paciga M, Schmiel D, Rawat R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Oct 1;23(19):5666-5670. doi: 10.1158/1078-0432.CCR-16-0663. Epub 2017 Feb 24.


FDA Approval Summary: TAS-102.

Marcus L, Lemery SJ, Khasar S, Wearne E, Helms WS, Yuan W, He K, Cao X, Yu J, Zhao H, Wang Y, Stephens O, Englund E, Agarwal R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jun 15;23(12):2924-2927. doi: 10.1158/1078-0432.CCR-16-2157. Epub 2017 Feb 17.


U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jul 15;23(14):3484-3488. doi: 10.1158/1078-0432.CCR-16-0712. Epub 2017 Jan 13.


Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.

Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, Mitchell JA, O'Lone R, Parish ST, Piche MS, Reed DM, Reichmann G, Ryan PC, Stebbings R, Walker M.

Cytokine. 2016 Sep;85:101-8. doi: 10.1016/j.cyto.2016.06.006. Epub 2016 Jun 13. Review.


FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.

Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.

Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. Review.


Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells.

Maynard CL, Hatton RD, Helms WS, Oliver JR, Stephensen CB, Weaver CT.

J Exp Med. 2009 Feb 16;206(2):343-57. doi: 10.1084/jem.20080950. Epub 2009 Feb 9.


Modulation of NFAT-dependent gene expression by the RhoA signaling pathway in T cells.

Helms WS, Jeffrey JL, Holmes DA, Townsend MB, Clipstone NA, Su L.

J Leukoc Biol. 2007 Aug;82(2):361-9. Epub 2007 May 14.


Transforming growth factor-beta induces development of the T(H)17 lineage.

Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT.

Nature. 2006 May 11;441(7090):231-4. Epub 2006 Apr 30.


Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.

Coffield VM, Helms WS, Jiang Q, Su L.

J Exp Med. 2004 Nov 15;200(10):1315-24. Epub 2004 Nov 8.


Natural selection and high heels.

Smith EO, Helms WS.

Foot Ankle Int. 1999 Jan;20(1):55-7. No abstract available.


Supplemental Content

Loading ...
Support Center